Verna Goa, March 20, 2018 -- GervanoRA Projects India’s Pharmaceutical and Medical Device Market to Reach $77.5 Billion by 2022
According to a new country report "GER00011CI India Insights: Healthcare Industry, Policies, Regulations and PESTLE Analysis" published by GervanoRA Data Services (GDS), India’s pharmaceutical and medical device market is expected to reach $77.5 billion by 2022.
India is one of the largest pharmaceutical producers in the world, driven by low cost of production and highest number of US FDA approved manufacturing plants. India is amongst topmost supplier of anti-retroviral, anti-tubercular and anti-malarial drugs worldwide. Healthcare is one of the fastest growing industries in India, and largest in terms of employment as well as revenue.
Ramu Jadhav, Managing Director of life sciences at GDS commented, “India is the emerging dominant force in the Asia region, driven by robust economic growth and second largest population in the world, with high prevalence of chronic diseases”.
Jadhav continued: “The pace of innovation in branded generics, biopharmaceuticals and medical devices segments have been unprecedented, and will spearhead growth over the forecast period.
Generics which currently account for over 65% of the India market, is estimated to reach $53.4 billion by 2022 growing at a CAGR of 11.3% between 2018-2022. While OTC segment will experience moderate growth to reach $8.8 billion by 2022.
Jadhav added, “Rapid movement of growth trend has become a new norm in Indian healthcare industry. In the past one year we have observed emergence of new growth drivers as well as barriers. One such example is National Health Protection Scheme (NHPS), announced in 2018, to provide health cover of up to $7700 per year to 100 million poor and vulnerable families (covering around 500 million individuals). However, implementation of such policies demands active participation of all the industry stakeholders and infrastructural scale up which is quite difficult to achieve in the shorter time frame.”
Industry is also facing challenges such as heavy reliance on API import, pricing and taxation pressure. Similarly, current device suppliers are not able to meet the robust market demand, leading to heavy dependence on imports.
To read GervanoRA’s India Insights full report, please visit https://www.gervanora.com/ger00011ci/ or you can inquire through [email protected]
Recently Published Other Reports
- Rheumatoid Arthritis: Global Market Analysis 2017 and Forecast 2018-2028
- Psoriasis: Global Market Analysis 2017 and Forecast 2018-2028
- Type 1 Diabetes: Global Market Analysis 2017 and Forecast 2018-2028
- Activated PI3K Delta Syndrome: Global Market Analysis 2017 and Forecast 2018-2028
- Osteoarthritis Pipeline Analysis Insights 2018
- GER0004CI Germany Insights: Healthcare Industry, Policies, Regulations and PESTLE Analysis
About GervanoRA
GervanoRA Data Services LLP is a premier provider of syndicated research reports, custom research reports and consulting services, based in Goa, India. GDS aims to deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial views of the competitive framework, and future market trends.
At GervanoRA Data Services, we're playing our part to help clients stay ahead of the curve. We collaboratively work with a wide range of organizations (KOLs) to garner valuable key insights.
Contacts
India (Head Office)
Mr. Ramu Jadhav
GervanoRA Data Services LLP
Verna, Goa - 403722
India
[email protected]
Ph. No. +91 832-2783283
United States
[email protected]
+1(901)210-7246
United Kingdom
[email protected]
+44-7894444092
New Zealand
[email protected]
+64-20-4545453
Connect with us on LinkedIn @ https://in.linkedin.com/company/gervanora-data-services-llp
India (Head Office) Mr. Ramu Jadhav GervanoRA Data Services LLP Verna, Goa - 403722 India [email protected] Ph. No. +91 832-2783283


SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 



